Anti-Viral Compounds


Despite successful therapeutic progress targeting a variety of viral infections and diseases (e.g. HIV, Hep B, herpes viruses, etc.), antiviral drug development continues to be plagued with toxic side effects.  Selective targeting of viruses is difficult to achieve due in part to the obligate intracellular ‘parasitic’ nature of viruses. Also, the classical nucleoside analog antiviral agents have typically had effects on the nucleic acid synthesis of normal cells, resulting in toxic side effects in tissues with rapidly dividing cells.

Whether directly targeting viral replication (e.g. inhibiting DNA, RNA or protein synthesis1,2,4), boosting the host immune system’s response via interferon therapy5 or utilizing combination therapies (e.g. targeting chronic HCV via Ribavirin and peg-IFN alpha3), bone marrow toxicity is often associated with many of these drugs.

ReachBio has worked with a number of clients during preclinical development of antiviral agents to help them predict and rank the potential of their drug candidates to induce myelosuppression (anemia, neutropenia, thrombocytopenia).

Typical Applications and Assays for Anti-Viral Compounds

Please contact us to discuss your project needs.


Related Topics:

Predictive Hemotoxicity Assays

CFC Assays and Applications for Normal Tissues

 Insert pic of a virsus (Rob to acquire)





1. J.P. Sommadossi et. al., Antimicrobial Agents and Chemotherapy. 1987; 31: 452-454.
2. R. Dornsife et. al., Antimicrobial Agents and Chemotherapy. 1996 (Feb); 40(2): 514-519.
3. C.M. Drapeau et. al., J Chemother. 2008 (Oct); 20(5): 648-651.
4. A. Lam et. al., Antimicrobial Agents and Chemotherapy. 2011 (Jun); 55(6): 2566-2575.
5. M. Peck-Radosavljevic et. al., Gastroenterology. 2002; 123: 141-151.